本帖最后由 老马 于 2013-3-13 13:43 编辑 $ ^* E! v- n6 {1 m! T
0 C8 ]9 t5 b) N& X
健择(吉西他滨)+顺铂+阿瓦斯汀
, f# M4 D6 c8 E- k" Q6 ~$ |( H Gemzar +Cisplatin + Avastin0 Z0 ~ N) N' V& E
http://annonc.oxfordjournals.org/content/21/9/1804.full9 o/ ~% \5 i/ i2 \4 n" Z
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
& c5 J4 X& I: E8 {- |Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
& h0 }5 `6 E* UResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
) I/ ]- `2 Q6 ~
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 632)
7 ~" r2 ~* \( l* @* {
华为网盘附件:* \4 F; a' m J
【华为网盘】ava.JPG
% g7 H( J0 f8 e- z |